Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors

Figures

• 

  Figure 1. Flowchart of case selection for the French cardio-oncology units and VigiBase. CAE, cardiac adverse event; ICI, immune checkpoint inhibitor; ICSR, individual case safety report.

• 

  Figure 2. Immune checkpoint inhibitor-associated CAE rates in early (<90 days) and late (≥90 days) cases from three French cardio-oncology unit databases (A) and in VigiBase (B). CAE, cardiac adverse event; LVSD, left ventricular systolic dysfunction; ns, not significant.